Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Malaria and Prophylaxis of Malaria.

Pharmaceuticals (Basel)

Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium.

Published: July 2019

Tafenoquine (an 8-aminoquinoline) was approved by the Food and Drug Administration (FDA) in 2018 for the radical cure of malaria and preventive action against malaria. Despite the fact that the mechanism of action of the drug remains unclear, all studies indicated that a metabolite is responsible for its efficacy. Routes for the preparation of the drug are described.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789594PMC
http://dx.doi.org/10.3390/ph12030115DOI Listing

Publication Analysis

Top Keywords

radical cure
8
cure malaria
8
tafenoquine 2018
4
2018 novel
4
novel fda-approved
4
fda-approved prodrug
4
prodrug radical
4
malaria
4
malaria prophylaxis
4
prophylaxis malaria
4

Similar Publications

Is There a Role for Surgery in the Treatment of Metastatic Urothelial Carcinoma?

J Clin Med

December 2024

Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson University Hospital, 195 Albany St., New Brunswick, NJ 08901, USA.

: Bladder cancer is one of the most common malignancies worldwide with over 614,000 new cases and 220,000 deaths annually. Five percent of newly diagnosed patients have metastatic disease. Metastatic urothelial carcinoma (mUC) is primarily treated with cisplatin-based chemotherapy, immunotherapy, targeted therapy, or combinations.

View Article and Find Full Text PDF

The widespread utilization of nail gels in the cosmetic and beauty industry, with an anticipated market value of US $65.8 Million by 2026, has raised concerns about health risks associated with conventional compositions containing monomeric acrylate reactive diluents. Technical challenges, such as oxygen inhibition leading to incomplete cure and hence tackiness after curing, further complicate their application process.

View Article and Find Full Text PDF

A 69-year-old man with systemic sclerosis and interstitial pneumonia presented with an abnormal shadow in the right upper lung lobe. A thoracoscopic needle biopsy was performed on the right upper lobe lesion, and Mycobacterium malmoense was identified by 16S rRNA and rpoB gene sequencing. Surgical treatment was performed to obtain a radical cure, and lung squamous cell carcinoma and M.

View Article and Find Full Text PDF
Article Synopsis
  • This study explored the effectiveness and safety of combining chemoradiotherapy (CRT) with local consolidative therapy (LCT) for patients with Stage IV non-small cell lung cancer (NSCLC) and oligometastases.
  • During the Phase II trial involving 19 patients, the treatment resulted in a 58% response rate, median progression-free survival of 8.6 months, and a two-year survival rate of 68.4%.
  • The findings suggest that this aggressive treatment approach may prolong survival and improve local control without severe adverse events.
View Article and Find Full Text PDF

Colon cancer is a major global health threat. Early detection and treatment are crucial for improving survival rates. Conventional methods, like colonoscopies and CT scans, have limitations, emphasizing the need for innovative strategies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!